Thousands of people from Sierra Leone, Liberia, and Guinea have died in the past few months because of the highly alarming Ebola outbreak. As of today, the death toll in West Africa had already passed 8,000. As a result, an evidence of a groundbreaking and impactful international effort is currently being demanded from several government and health institutions by the members of the international community.
Thankfully, the World Health Organization (WHO), the Wellcome Trust, a number of drug companies, and Médecins Sans Frontiéres (Doctors Without Borders) have decided to employ an efficient and fast-track type of treatment in order to resolve the growing death toll in West Africa.
In Liberia, a major clinical Ebola drug trial had already started in order to effectively determine whether the antiviral drug called brincidofovir which was recently developed by several pharmaceutical companies is capable of treating the victims of the dreaded Ebola virus effectively or not. Although the brincidofovir is being used in the drug trial, a group of scientists from Oxford University had confirmed that it is still important to keep in mind that the newly developed drug is not a miracle cure to Ebola. As a matter of fact, it remains uncertain up to this point whether the said drug can actually reduce the increasing number of victims in the Ebola-stricken areas in West Africa or not. Medical charity has also confirmed that those who will participate in the drug trials are those patients who have decided on their own to become part of the medical treatment trial. It has been reported that all patients affected by the Ebola virus are given the freedom to choose as to whether or not they would like to receive trial doses that can potentially counter the Ebola virus’ fatal effects.
Scientists from Oxford University believe that brincidofovir is the most apt antiviral drug which can be used in tackling the dreadful Ebola virus in West Africa since brincidofovir has been proven to be effective in fighting Ebola-infected cells in the laboratory tests previously conducted by the said group of brilliant scientists from Oxford. In addition, it has also been proven safe to use in over a thousand patients who have decided to participate in the previous Ebola drug trials. According to scientists, once it is affirmed that brincidofovir is effective and 100% useful in treating the Ebola virus, the drug can be conveniently taken by patients in tablet form.
Although there are no guarantees that the new drug will be able to reduce the number of Ebola victims in West Africa, the science community remains hopeful that the world is only one step closer to countering the effects of the Ebola virus especially now that there is finally a potential treatment for the highly fatal and contagious disease in West Africa.
However, according to experts, even though this drug trial is a crucial element in fully solving the Ebola outbreak in West Africa, there is still a need for patients to observe prompt and basic medical care on their body’s current condition because it could slightly increase their chances of survival from the deadly Ebola virus. For example, replacing fluids and electrolytes can positively contribute to improving West Africa’s overall fatality rate aside from treating the early symptoms of Ebola (Mundasad, 2014).